Sandbox Reserved 1660: Difference between revisions

Line 41:

Additionally, there are two <scene name='86/868193/Oligosaccharides/1'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/1'>site</scene> is located at the A and F pockets in the region of the alpha helices.

Additionally, there are two <scene name='86/868193/Oligosaccharides/1'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/1'>site</scene> is located at the A and F pockets in the region of the alpha helices<ref name="site">Schiefner, A.; Fujio, M.; Wu, D.; Wong, C.-H.; Wilson, I. A. Structural Evaluation of Potent NKT-Cell Agonists: Implications for Design of Novel Stimulatory Ligands. J Mol Biol 2009, 394 (1), 71–82. https://doi.org/10.1016/j.jmb.2009.08.061</ref>.

Line 50:

NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR.

NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR<ref name="site"/>.

<scene name='86/868193/Morph_3gmq_4f7c_u4681/1'>Conformational variations</scene> between CD1d no ligand and structure of bovine CD1d with bound C12-di-sulfatide.

Line 69:

The presence of high amount of CD1d proteins on the cell surface of NKT cells gives rise to a novel type of NKT cells. This larger amount of CD1d proteins allows the Cd1d high NKT cells to bind more alpha-galactosylceramide molecules and therefore to can produce greater levels of interleukin-4 and INF-gamma molecules leading to possible therapeutical effects<ref>Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328</ref>.

The presence of high amount of CD1d proteins on the cell surface of NKT cells gives rise to a novel type of NKT cells. This larger amount of CD1d proteins allows the Cd1d high NKT cells to bind more alpha-galactosylceramide molecules and therefore to can produce greater levels of interleukin-4 and INF-gamma molecules leading to possible therapeutical effects<ref>Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328.</ref>.

Sandbox Reserved 1660: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 41: / Line 41: @@
 <p align="justify">
-Additionally, there are two <scene name='86/868193/Oligosaccharides/1'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/1'>site</scene> is located at the A and F pockets in the region of the alpha helices.
+Additionally, there are two <scene name='86/868193/Oligosaccharides/1'>oligosaccharides</scene> bound to the alpha chain via [https://en.wikipedia.org/wiki/N-linked_glycosylation N-glycosylations] and three types of small molecules bound to that protein<ref name="Structure"/>. CD1d molecules are structurally similar to [[Major Histocompatibility Complex Class I]], but present lipid antigens as opposed to peptides and the cleft where the ligand can bind its protein is different between MHC molecules and CD1d molecules. Indeed, the hydrophobic cleft of CD1d has a narrow opening.The recognition between the protein and its ligand occurs at a specific spot which creates an appropriate environment for the interaction to happen. This <scene name='86/868193/Site/1'>site</scene> is located at the A and F pockets in the region of the alpha helices<ref name="site">Schiefner, A.; Fujio, M.; Wu, D.; Wong, C.-H.; Wilson, I. A. Structural Evaluation of Potent NKT-Cell Agonists: Implications for Design of Novel Stimulatory Ligands. J Mol Biol 2009, 394 (1), 71–82. https://doi.org/10.1016/j.jmb.2009.08.061</ref>.
 </p>
@@ Line 50: / Line 50: @@
 <p align="justify">
-NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR.
+NTK cells are a subset of [https://en.wikipedia.org/wiki/T_cell T cells] (which play a central role in the immune response) that are activated by CD1d-glycolipid complexes. α-GalCer is a potent NKT cell agonist when presented by CD1d. The stability of the CD1d-glycolipid complexes has an impact on the [https://en.wikipedia.org/wiki/Cytokine cytokine] release (cell signaling). Conformational variations that would stabilize the F’-pocket (primary site of interaction with the T cell receptor, NKT TCR) might increase CD1d affinity for the NKT TCR<ref name="site"/>.
 </p>
 <scene name='86/868193/Morph_3gmq_4f7c_u4681/1'>Conformational variations</scene> between CD1d no ligand and structure of bovine CD1d with bound C12-di-sulfatide.
@@ Line 69: / Line 69: @@
 <p align="justify">
-The presence of high amount of CD1d proteins on the cell surface of NKT cells gives rise to a novel type of NKT cells. This larger amount of CD1d proteins allows the Cd1d high NKT cells to bind more alpha-galactosylceramide molecules and therefore to can produce greater levels of interleukin-4 and INF-gamma molecules leading to possible therapeutical effects<ref>Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328</ref>.
+The presence of high amount of CD1d proteins on the cell surface of NKT cells gives rise to a novel type of NKT cells. This larger amount of CD1d proteins allows the Cd1d high NKT cells to bind more alpha-galactosylceramide molecules and therefore to can produce greater levels of interleukin-4 and INF-gamma molecules leading to possible therapeutical effects<ref>Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012). Recognition of CD1d-restricted antigens by natural killer T cells. Nature reviews. Immunology, 12(12), 845–857. https://doi.org/10.1038/nri3328.</ref>.
 </p>